Caseware UK (AP4) 2025.0.111 2025.0.111 2026-04-302026-04-30false2025-05-01The principal activity of the company continued to be that of sale of protein products.Directors22falsetrueThe members have not required the company to obtain an audit in accordance with section 476 of the Companies Act 2006.false 11993367 2025-05-01 2026-04-30 11993367 2024-05-01 2025-04-30 11993367 2026-04-30 11993367 2025-04-30 11993367 c:Director1 2025-05-01 2026-04-30 11993367 d:PlantMachinery 2025-05-01 2026-04-30 11993367 d:PlantMachinery 2026-04-30 11993367 d:PlantMachinery 2025-04-30 11993367 d:PlantMachinery d:OwnedOrFreeholdAssets 2025-05-01 2026-04-30 11993367 d:FurnitureFittings 2025-05-01 2026-04-30 11993367 d:FurnitureFittings 2026-04-30 11993367 d:FurnitureFittings 2025-04-30 11993367 d:FurnitureFittings d:OwnedOrFreeholdAssets 2025-05-01 2026-04-30 11993367 d:ComputerEquipment 2025-05-01 2026-04-30 11993367 d:ComputerEquipment 2026-04-30 11993367 d:ComputerEquipment 2025-04-30 11993367 d:ComputerEquipment d:OwnedOrFreeholdAssets 2025-05-01 2026-04-30 11993367 d:OwnedOrFreeholdAssets 2025-05-01 2026-04-30 11993367 d:PatentsTrademarksLicencesConcessionsSimilar 2025-05-01 2026-04-30 11993367 d:CopyrightsPatentsTrademarksServiceOperatingRights 2026-04-30 11993367 d:CopyrightsPatentsTrademarksServiceOperatingRights 2025-04-30 11993367 d:CurrentFinancialInstruments 2026-04-30 11993367 d:CurrentFinancialInstruments 2025-04-30 11993367 d:Non-currentFinancialInstruments 2026-04-30 11993367 d:Non-currentFinancialInstruments 2025-04-30 11993367 d:CurrentFinancialInstruments d:WithinOneYear 2026-04-30 11993367 d:CurrentFinancialInstruments d:WithinOneYear 2025-04-30 11993367 d:Non-currentFinancialInstruments d:AfterOneYear 2026-04-30 11993367 d:Non-currentFinancialInstruments d:AfterOneYear 2025-04-30 11993367 d:ShareCapital 2026-04-30 11993367 d:ShareCapital 2025-04-30 11993367 d:RetainedEarningsAccumulatedLosses 2026-04-30 11993367 d:RetainedEarningsAccumulatedLosses 2025-04-30 11993367 c:FRS102 2025-05-01 2026-04-30 11993367 c:AuditExempt-NoAccountantsReport 2025-05-01 2026-04-30 11993367 c:FullAccounts 2025-05-01 2026-04-30 11993367 c:PrivateLimitedCompanyLtd 2025-05-01 2026-04-30 11993367 d:CopyrightsPatentsTrademarksServiceOperatingRights d:OwnedIntangibleAssets 2025-05-01 2026-04-30 11993367 e:PoundSterling 2025-05-01 2026-04-30 iso4217:GBP xbrli:pure

Registered number: 11993367









PROTEIN REBEL LIMITED







UNAUDITED

FINANCIAL STATEMENTS

FOR THE YEAR ENDED 30 APRIL 2026

 
PROTEIN REBEL LIMITED
REGISTERED NUMBER: 11993367

BALANCE SHEET
AS AT 30 APRIL 2026

2026
2025
Note
£
£

Fixed assets
  

Intangible assets
 4 
2,409
3,089

Tangible assets
 5 
1,342
1,764

  
3,751
4,853

Current assets
  

Stocks
  
46,898
35,630

Debtors: amounts falling due within one year
 6 
2,549
1,753

Cash at bank and in hand
  
25,444
18,927

  
74,891
56,310

Creditors: amounts falling due within one year
 7 
(297,935)
(219,411)

Net current liabilities
  
 
 
(223,044)
 
 
(163,101)

Total assets less current liabilities
  
(219,293)
(158,248)

Creditors: amounts falling due after more than one year
 8 
-
(64,923)

  

Net liabilities
  
(219,293)
(223,171)


Capital and reserves
  

Called up share capital 
  
1
1

Profit and loss account
  
(219,294)
(223,172)

  
(219,293)
(223,171)

Page 1

 
PROTEIN REBEL LIMITED
REGISTERED NUMBER: 11993367
    
BALANCE SHEET (CONTINUED)
AS AT 30 APRIL 2026

The directors consider that the Company is entitled to exemption from audit under section 477 of the Companies Act 2006 and members have not required the Company to obtain an audit for the year in question in accordance with section 476 of the Companies Act 2006.

The directors acknowledge their responsibilities for complying with the requirements of the Companies Act 2006 with respect to accounting records and the preparation of financial statements.

The financial statements have been prepared in accordance with the provisions applicable to companies subject to the small companies regime and in accordance with the provisions of FRS 102 Section 1A - small entities.

The financial statements have been delivered in accordance with the provisions applicable to companies subject to the small companies regime.

The Company has opted not to file the profit and loss account in accordance with provisions applicable to companies subject to the small companies' regime.

The financial statements were approved and authorised for issue by the board and were signed on its behalf by: 




................................................
Mr T Boote
Director

Date: 22 September 2026

The notes on pages 3 to 7 form part of these financial statements.
Page 2

 
PROTEIN REBEL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026

1.


General information

Protein Rebel Limited is a private company limited by shares incorporated in England and Wales. The
registered office is The Highlands, Cross Lane,  Minshull Vernon, Crewe, Cheshire, CW1 4RG.

2.Accounting policies

 
2.1

Basis of preparation of financial statements

The financial statements have been prepared under the historical cost convention unless otherwise specified within these accounting policies and in accordance with Financial Reporting Standard 102, the Financial Reporting Standard applicable in the UK and the Republic of Ireland and the Companies Act 2006. The disclosure requirements of Section 1A of FRS 102 have been applied other than where additional disclosure is required to show a true and fair view.

The following principal accounting policies have been applied:

 
2.2

Going concern

Not withstanding the net liabilities at 30 April 2026 of £219,293, at the time of approving the financial statements, the director has a reasonable expectation that the company has adequate resources to continue in operational existence for the foreseeable future, through the continued financial support of the directors.

Thus the director continues to adopt the going concern basis of accounting in preparing the financial
statements.

 
2.3

Revenue

Revenue is recognised to the extent that it is probable that the economic benefits will flow to the Company and the revenue can be reliably measured. Revenue is measured as the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes. The following criteria must also be met before revenue is recognised:

Sale of goods

Revenue from the sale of goods is recognised when all of the following conditions are satisfied:
∙the Company has transferred the significant risks and rewards of ownership to the buyer;
∙the Company retains neither continuing managerial involvement to the degree usually associated with ownership nor effective control over the goods sold;
∙the amount of revenue can be measured reliably;
∙it is probable that the Company will receive the consideration due under the transaction; and
∙the costs incurred or to be incurred in respect of the transaction can be measured reliably.

 
2.4

Finance costs

Finance costs are charged to profit or loss over the term of the debt using the effective interest method so that the amount charged is at a constant rate on the carrying amount. Issue costs are initially recognised as a reduction in the proceeds of the associated capital instrument.

Page 3

 
PROTEIN REBEL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026

2.Accounting policies (continued)

 
2.5

Intangible assets

Intangible assets are initially recognised at cost. After recognition, under the cost model, intangible assets are measured at cost less any accumulated amortisation and any accumulated impairment losses.

All intangible assets are considered to have a finite useful life. If a reliable estimate of the useful life cannot be made, the useful life shall not exceed ten years.

 Amortisation is provided on the following bases:

Websites
-
10%
Straight line

 
2.6

Tangible fixed assets

Tangible fixed assets under the cost model are stated at historical cost less accumulated depreciation and any accumulated impairment losses. Historical cost includes expenditure that is directly attributable to bringing the asset to the location and condition necessary for it to be capable of operating in the manner intended by management.

Depreciation is charged so as to allocate the cost of assets less their residual value over their estimated useful lives, .

Depreciation is provided on the following basis:

Plant and machinery
-
20%
reducing balance
Fixtures and fittings
-
20%
reducing balance
Computer equipment
-
33%
Straight line

The assets' residual values, useful lives and depreciation methods are reviewed, and adjusted prospectively if appropriate, or if there is an indication of a significant change since the last reporting date.

Gains and losses on disposals are determined by comparing the proceeds with the carrying amount and are recognised in profit or loss.

 
2.7

Stocks

Stocks are stated at the lower of cost and net realisable value, being the estimated selling price less costs to complete and sell. Cost is based on the cost of purchase on a first in, first out basis. Work in progress and finished goods include labour and attributable overheads.

At each balance sheet date, stocks are assessed for impairment. If stock is impaired, the carrying amount is reduced to its selling price less costs to complete and sell. The impairment loss is recognised immediately in profit or loss.

 
2.8

Debtors

Short-term debtors are measured at transaction price, less any impairment. Loans receivable are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method, less any impairment.

Page 4

 
PROTEIN REBEL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026

2.Accounting policies (continued)

 
2.9

Cash and cash equivalents

Cash is represented by cash in hand and deposits with financial institutions repayable without penalty on notice of not more than 24 hours. Cash equivalents are highly liquid investments that mature in no more than three months from the date of acquisition and that are readily convertible to known amounts of cash with insignificant risk of change in value.

 
2.10

Creditors

Short-term creditors are measured at the transaction price. Other financial liabilities, including bank loans, are measured initially at fair value, net of transaction costs, and are measured subsequently at amortised cost using the effective interest method.


3.


Employees

The average monthly number of employees, including directors, during the year was 2 (2025 - 2).


4.


Intangible assets




Websites

£



Cost


At 1 May 2025
6,800



At 30 April 2026

6,800



Amortisation


At 1 May 2025
3,711


Charge for the year on owned assets
680



At 30 April 2026

4,391



Net book value



At 30 April 2026
2,409



At 30 April 2025
3,089



Page 5

 
PROTEIN REBEL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026

5.


Tangible fixed assets


Plant and machinery
Fixtures and fittings
Computer equipment
Total

£
£
£
£



Cost or valuation


At 1 May 2025
1,390
853
1,183
3,426



At 30 April 2026

1,390
853
1,183
3,426



Depreciation


At 1 May 2025
538
171
953
1,662


Charge for the year on owned assets
170
137
115
422



At 30 April 2026

708
308
1,068
2,084



Net book value



At 30 April 2026
682
545
115
1,342



At 30 April 2025
852
682
230
1,764


6.


Debtors

2026
2025
£
£


Trade debtors
-
624

Prepayments and accrued income
2,549
1,129

2,549
1,753


Page 6

 
PROTEIN REBEL LIMITED
 
 
 
NOTES TO THE FINANCIAL STATEMENTS
FOR THE YEAR ENDED 30 APRIL 2026

7.


Creditors: Amounts falling due within one year

2026
2025
£
£

Trade creditors
3,442
3,138

Amounts owed to associates
64,923
-

Other taxation and social security
8,900
7,562

Other creditors
218,136
206,750

Accruals and deferred income
2,534
1,961

297,935
219,411



8.


Creditors: Amounts falling due after more than one year

2026
2025
£
£

Amounts owed to associates
-
64,923

-
64,923


 
Page 7